This episode covers critical regulatory developments impacting ASEAN countries, focusing on FTA negotiations, WHO South-East Asia’s strategic health initiatives, Emergency Use Authorization for medical innovations, tuberculosis control, and Malaysia’s new insolvency legislation.

Highlights include Indonesia’s efforts to accelerate vaccine approval processes with a 100-day pandemic response target and regulatory support for precision medicine and cell therapy. The Malaysian Cross-Border Insolvency Act 2026 introduces enhanced legal frameworks for international insolvency cooperation. Additionally, the WHO South-East Asia Regional Committee’s upcoming session will address key health priorities, including tuberculosis elimination and health system resilience.

For more information, visit the Carver Agents website.

Articles mentioned:

1. CM 3943 2026 REV 1
2. Health ministers of WHO South-East Asia Region meeting next week to advance action on key health priorities
3. HSA Charges Five Men for Alleged Trafficking of Etomidate Vaporiser Pods; One Man Caught with $870,000 Worth of Pods
4. Laporan Kelembagaan LPS Triwulan 2 2026
5. Laporan Kelembagaan LPS Triwulan II 2026
6. BPOM Siapkan Regulasi Dukung Pengembangan Precision Medicine dan Terapi Sel
7. Siaran Pers: Perkuat Penegakan Hukum, OJK Tetapkan 1.277 Sanksi Atas Pelanggaran Peraturan Pasar Modal dan Kepatuhan Pelaporan
8. Akta Insolvensi Rentas Sempadan 2026 [Akta 877] Berkuat Kuasa Pada 28 Ogos 2026
9. Thailand cuts visa-free stays from 60 days to 30 days for 60 countries, including Malaysia
10. Antisipasi Pandemi Baru, Indonesia Jadi Negara Ketiga Penguji Target Vaksin 100 Hari